EBS logo

Emergent BioSolutions Inc. (EBS)

$5.61

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on EBS

Market cap

$288439171

EPS

-3.46

P/E ratio

--

Price to sales

0.46

Dividend yield

--

Beta

2.372596

Price on EBS

Previous close

$5.81

Today's open

$5.90

Day's range

$5.55 - $5.90

52 week range

$4.36 - $14.06

Profile about EBS

CEO

Joseph Papa

Employees

900

Headquarters

Gaithersburg, MD

Exchange

New York Stock Exchange

Shares outstanding

51415182

Issue type

Common Stock

EBS industries and sectors

Healthcare

Pharmaceuticals

News on EBS

Asimov and Emergent Biosolutions Announce Cell Line Development Partnership to Advance Novel Antibodies Against Ebola

BOSTON and GAITHERSBURG, Md., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Asimov, the company building an AI-native synthetic biology platform to advance therapeutic development, and Emergent Biosolutions (NYSE: EBS), a leading global public health company, today announced a cell line development partnership.

news source

GlobeNewsWire • Nov 16, 2026

news preview

Emergent BioSolutions to Participate in Jefferies Global Healthcare Conference

GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) announced today that members of the company's senior management team will participate in the Jefferies Global Healthcare Conference in London, November 16-19, 2026. Management will present via webcast on November 18 at 8:00am – 8:25am UTC/GMT (3:00am ET). A replay of the presentation will be available on the webcast page linked above for approximately three months. Visit Emergent's Investor Relations page to learn more.

news source

Business Wire • Nov 10, 2026

news preview

Emergent BioSolutions: A Turnaround Still Waiting For Consistent Execution

Emergent BioSolutions remains a hold as commercial recovery is uncertain despite progress on cost savings and debt reduction. EBS lowered FY26 revenue and EBITDA guidance, citing government procurement delays and persistent pricing pressure in the U.S. naloxone market. Gross margin and profitability deteriorated sharply, with adjusted EBITDA swinging to a $4.6M loss and a net loss of $32.7M in 3Q26.

news source

Seeking Alpha • Nov 6, 2026

news preview

Emergent BioSolutions Receives $22.3 Million Delivery Order Modification to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War

GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS--Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has received a modification exercising an option period under its existing delivery order valued at up to $22.3 million to supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of War (DoW). The first delivery, which is valued at approximately $7.4 million, will begin this year, and remaining deliveries are expected in 2027. This order is under Emergent's existing indefinite-delivery/.

news source

Business Wire • Nov 4, 2026

news preview

Emergent BioSolutions: 3 Key Takeaways for Long-Term Investors

Full-year revenue guidance was updated to $600 million to $645 million. Restructuring actions are expected to generate $40 million in annualized savings.

news source

The Motley Fool • Nov 3, 2026

news preview

Emergent Biosolutions Q3 Earnings Call Highlights

Emergent Biosolutions NYSE: EBS reported third-quarter revenue within its guidance range and updated its full-year outlook, while continuing a multiyear transformation focused on cost control, debt reduction, medical countermeasures and naloxone access.

news source

MarketBeat • Nov 2, 2026

news preview

Emergent BioSolutions Inc. (EBS) Q3 2026 Earnings Call Transcript

Emergent BioSolutions Inc. (EBS) Q3 2026 Earnings Call Transcript

news source

Seeking Alpha • Nov 3, 2026

news preview

Emergent Biosolutions Reports Third Quarter 2026 Financial Results

GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) today reported financial results for the third quarter ended September 30, 2026. “Emergent's third-quarter results, which include revenue of $110.0 million inline with our guidance, were primarily driven by our diverse biodefense/medical countermeasures and naloxone portfolio, underscoring the importance of disciplined execution as we advance our multi-year transformation,” said Joe Papa, president and chief executive of.

news source

Business Wire • Nov 2, 2026

news preview

Emergent BioSolutions Announces Retirement of Chief Financial Officer Richard S. Lindahl

GAITHERSBURG, Md.--(BUSINESS WIRE)---- $EBS--Emergent BioSolutions Inc. (NYSE: EBS) today announced that Richard S. Lindahl, executive vice president, chief financial officer, will retire from the Company effective December 31, 2026. Frank Vargo, vice president, treasurer, will assume the role of interim chief financial officer effective January 1, 2027. To support a seamless transition, Rich will serve as a senior executive advisor from January 1 through March 31, 2027. “On behalf of the Board of Direc.

news source

Business Wire • Oct 16, 2026

news preview

Emergent BioSolutions to Report Third Quarter 2026 Financial Results on November 2, 2026

GAITHERSBURG, Md.--(BUSINESS WIRE)--Emergent BioSolutions Inc. (NYSE: EBS) will host a conference call on Monday, November 2, 2026, at 5:00 p.m. eastern time to discuss the financial results for the third quarter of 2026. Participants can access the conference call via webcast and also by visiting the Investors page of Emergent's website. Participants can pre-register for the teleconference at the following link and will receive an email with a calendar reminder, dial-in number and a unique cod.

news source

Business Wire • Oct 15, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Emergent BioSolutions Inc.

Open an M1 investment account to buy and sell Emergent BioSolutions Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in EBS on M1